Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy
Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy have?
Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy has 83 citations in the OpenAlex counts ScholarIQ stores.
When was Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy published?
Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy has 2017 year in the ScholarIQ index.
What is the open-access status of Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy?
Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy has closed oa status in the ScholarIQ index.
What is the DOI of Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy?
The DOI for Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy is on the source record.
What is the PMID of Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy?
The PMID for Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy is on the source record.
What is the OpenAlex record for Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy?
The OpenAlex for Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and <i>T</i> <sub>1</sub> – <i>T</i> <sub>2</sub> dual mode MRI guided photodynamic/photothermal therapy is on the source record.